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Evaluating 5-Nitrofurans as Trypanocidal Agents
Christopher Bot,a* Belinda S. Hall,a* Guzmán Álvarez,b Rossanna Di Maio,b Mercedes González,b Hugo Cerecetto,b
Shane R. Wilkinsona
Queen Mary Pre-Clinical Drug Discovery Group, School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdoma; Grupo de
Química Medicinal, Facultad de Ciencias-Facultad de Química, Universidad de la República, Montevideo, Uruguayb
The nitroheterocycle nifurtimox, as part of a nifurtimox-eflornithine combination therapy, represents one of a limited number
of treatments targeting Trypanosoma brucei, the causative agent of human African trypanosomiasis. The mode of action of this
prodrug involves an initial activation reaction catalyzed by a type I nitroreductase (NTR), an enzyme found predominantly in
prokaryotes, leading to the formation of a cytotoxic unsaturated open-chain nitrile metabolite. Here, we evaluate the trypano-
cidal activities of a library of other 5-nitrofurans against the bloodstream form of T. brucei as a preliminary step in the identifi-
cation of additional nitroaromatic compounds that can potentially partner with eflornithine. Biochemical screening against the
purified enzyme revealed that all 5-nitrofurans were effective substrates for T. bruceiNTR (TbNTR), with the preferred com-
pounds having apparent kcat/Km values approximately 50-fold greater than those of nifurtimox. For several compounds, in vitro
reduction by this nitroreductase yielded products characterized by mass spectrometry as either unsaturated or saturated open-
chain nitriles. When tested against the bloodstream form of T. brucei, many of the derivatives displayed significant growth-in-
hibitory properties, with the most potent compounds generating 50% inhibitory concentrations (IC50s) around 200 nM. The
antiparasitic activities of the most potent agents were demonstrated to be NTR dependent, as parasites having reduced levels of
the enzyme displayed resistance to the compounds, while parasites overexpressing TbNTR showed hypersensitivity. We con-
clude that other members of the 5-nitrofuran class of nitroheterocycles have the potential to treat human African trypanosomia-
sis, perhaps as an alternative partner prodrug to nifurtimox, in the next generation of eflornithine-based combinational
therapies.
Human African trypanosomiasis (HAT) is caused by the pro-tozoan parasite Trypanosoma brucei. This infection is en-
demic throughout sub-SaharanAfrica, where transmission occurs
predominantly through the blood-feeding habits of its insect vec-
tor, the tsetse fly. In the last 15 years, greater political stability,
coupled with improved vector control and health surveillance
programs, has significantly reduced the number of new cases of
HAT from a high of around 450,000 in 1997 to about 30,000 in
2009 (1, 2). An important component of these plans involves the
treatment of infected individuals. However, the current therapies
against this disease are problematic, as they are costly, require
medical supervision for their administration, have limited effi-
cacy, and cause numerous adverse side effects (3). Additionally,
parasite strains refractory to certain front-line drugs have been
isolated from patients (2, 4, 5). Against this backdrop, there is an
urgent requirement for new antitrypanosomal treatments.
The interest in using nitrofuran derivatives to treat trypano-
somal infections began 60 years ago following reports that the
antibacterial agent nitrofurazone displayed antiparasitic activity
against Trypanosoma equiperdum and T. brucei (6–8). However,
clinical trials using this agent were suspended, as it became appar-
ent that it failed to totally eradicate parasitemia and it caused
several adverse side effects. The finding that trypanosomal infec-
tions can potentially be treatedwith nitrofurazone sparked a series
of screening programs to explore the parasite-killing activities of
other nitrofurans, with nifurtimox showing particular promise
against the causative agent of Chagas disease, Trypanosoma cruzi
(9). Marketed under the name Lampit (Bayer HealthCare AG),
nifurtimox, administered orally at 8 to 10 mg/kg/day in three
doses for 30 to 120 days, has formed one of the front-line treat-
ments against Chagas disease for 40 years (3). However, con-
cerns about gastrointestinal (GI) tract and central nervous system
(CNS) toxicity, the refractory nature of some T. cruzi strains, and
the limited efficacy and genotoxicity of nifurtimox led to the with-
drawal of its use as an anti-Chagasic chemotherapy in Brazil, Ar-
gentina, Chile, andUruguay; this resulted in reduced demand and
the cessation of production (10). Following successful trials of a
nifurtimox-eflornithine combination therapy (NECT) and its
subsequent addition to the WHO Essential Medicines List as a
treatment against the cerebral stage ofWest African trypanosomi-
asis (11), coupled with emerging reports about its effectiveness
against pediatric neuroblastoma (12), the manufacture of nifurti-
mox has recommenced with Bayer HealthCare AG, guaranteeing
supplies until 2017.
As withmany nitroheterocyclic agents, nifurtimoxmust undergo
activation before mediating its cytotoxic effects, reactions catalyzed
by nitroreductase (NTR) enzymes. Based on their cofactors, oxygen
sensitivities, and product profiles, NTRs can be broadly divided into
two groups (13). The ubiquitous oxygen-sensitive type II NTRs are
flavin (flavinmononucleotide [FMN] or flavin adenine dinucleotide
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[FAD])bindingNAD(P)H-dependent enzymes thatmediate the1e
reductionof thenitro substrate to formanitro radical anion(reaction
1) (14). In an aerobic environment, this radical undergoes futile cy-
cling, resulting in theproductionof superoxide anions and the regen-
eration of the parent nitro compound (reaction 2) (15):
RNO2 e

→ RNO2
● (1)
RNO2
●  O2→ RNO2 O2
● (2)
Initial findings showed that the addition of nifurtimox to T.
cruzi mitochondrial fractions or rat liver microsomes stimulated
the production of superoxide anions, leading to a widely accepted
view that its trypanocidalmode of action involves the induction of
oxidative stress (16, 17). Several trypanosomal enzymes, including
cytochrome P450 reductases and trypanothione reductase, have
been shown tomediate this reaction in vitro, appearing to confirm
earlier findings (18–20); this idea gained strength following re-
ports that trypanosomes had a limited enzymatic capacity to me-
tabolize reactive oxygen species (21). To date, the only functional
evidence for the involvement of superoxide anions in nifurtimox
toxicity is indirect, coming from studies on the superoxide dismu-
tase B1 isoform, where T. brucei SODB1 (TbSODB1) null mutants
and T. cruzi SODB1 (TcSODB1)-overexpressing cells are more
susceptible to the nitrofuran than are wild-type cells (22, 23). Ge-
netic manipulation of T. brucei or T. cruzi engineered to express
altered levels of oxygen-sensitive NTR activators—for example,
cytochrome P450 reductase, trypanothione reductase, or other
components of the trypanosomal oxidative defense system—gen-
erates parasites that display the same susceptibilities to nifurtimox
as control cells (24, 25). Therefore, as both trypanosomal and
mammalian cells can mediate futile cycling leading to superoxide
anion production, the induction of oxidative stress via activation
by oxygen-sensitiveNTRs does not explain the selectivity of nifur-
timox toward T. brucei or T. cruzi.
The other class of enzymes shown to activate nitroaromatic pro-
drugs are the oxygen-insensitive type I NTRs. These NAD(P)H-de-
pendent FMN-containing proteins have a restricted distribution,
as they are found predominantly in prokaryotes and were recently
identified in some protozoans (13, 26, 27). They catalyze two se-
quential 2e reduction reactions resulting in the conversion of the
nitro substrate to its hydroxylamine form via a nitroso intermedi-
ate (see reactions 3 and 4 below) (13). As this process does not
involve oxygen and does not result in the production of reactive
oxygen species, this activity is said to be “oxygen insensitive.”
RNO2 2e

→ RNO (3)
RNO 2e→ RNHOH (4)
Based on in vitro drug selection, gene manipulation, biochem-
ical analysis, and functional genomics, it is now clear that a type I
NTR expressed by trypanosomes plays a key role in nifurtimox
activation within the parasite itself (25, 27–30). The hydroxyl-
amine derivative generated from this activation event causes a
redistribution of electrons within the structure of the compound,
promoting cleavage of a C-O bond present on the furan ring (25).
This results in the formation of an unsaturated open-chain nitrile,
which, unlike the parental prodrug, displays equal cytotoxicity
toward trypanosomal and mammalian cells. For some nitro-
furans, the unsaturated open-chain nitrile can convert rapidly to a
nontoxic saturated state (31). Although nifurtimox does undergo
this change in vitro, this process occurs at a low rate (25). Based on
the accumulated data, the basis of nifurtimox selectivity against
trypanosomal pathogens appears to be directly related to the ex-
pression of type I NTRs, with the relative stability of the unsatu-
rated open-chain nitrile contributing to nitrofuran’s antiparasitic
activity.
The prostaglandin F2 synthase (also known as “old yellow
enzyme”) from T. cruzi is an atypical nitroreductase, displaying
features characteristic of both type I and II NTRs. In biochemical
studies, this enzyme was shown to catalyze the 2e reduction of
nifurtimox, but only under anaerobic conditions (32). Immuno-
precipitation of this activity in parasite lysates lowered the capac-
ity of the extract to reduce the nitrofuran, suggesting that it may
have an important role in nifurtimox metabolism (32). However,
functional studies on this enzyme have not yet been performed in
T. cruzi, while forT. brucei, cells expressing elevated levels of pros-
taglandin F2 synthase displayed the same susceptibility to nifur-
timox as control cells; this indicates that this enzyme does not play
a key role in the in vivometabolism of this prodrug (25).
Given the success of the NECT combination and the renewed
interest in using nitroaromatics for the treatment of trypanosomal
infections, we evaluated the growth-inhibitory properties of a ni-
trofuran series against the bloodstream form (BSF) of T. brucei.
Included in this compound set are a number of agents proposed to
mediate their activity through the inhibition of sterol biosynthesis
(33, 34). From these screens, six compounds showed significant
potency against trypanosomes andweremore selective toward the
parasite than nifurtimox in an activation mechanism where the
oxygen-insensitive NTR plays a key role.
MATERIALS AND METHODS
Chemicals. The nitrofuran structures used are shown in Table 1. Their
synthesis has been described previously (33–36).
Cell culturing. T. brucei brucei BSF trypomastigotes (MITat 427
strain; clone 221a and a derivative [2T1] engineered to constitutively ex-
press the tetracycline repressor protein) were cultured in Hirumi’s mod-
ified Iscove’s 9 (HMI-9) medium with 10% tetracycline-free fetal calf
serum (Autogen Bioclear) as described previously (37, 38). The 2T1 line
was grown in the presence of 1 g ml1 phleomycin. Transformed 2T1
parasite lines overexpressing T. bruceiNTR (TbNTR), prostaglandin F2
synthase (TbPGS), squalene epoxidase (TbSQE), or two cytochromeP450
reductases (TbCPR2 and TbCPR3; numbering is in accordance with that
of Portal et al. [39]) were maintained in the medium, supplemented with
2.5 g ml1 hygromycin.
African greenmonkey kidney (Vero) cells were grown at 37°C under a
5%CO2 atmosphere in RPMI 1640medium supplementedwith 10% fetal
calf serum, 20 mM HEPES (pH 7.4), 2 mM sodium glutamate, 2 mM
sodium pyruvate, 2.5 U ml1 penicillin, and 2.5 g ml1 streptomycin.
Plasmids. DNA fragments encoding TbPGS (GenBank accession no.
AB034727), TbSQE (XP_828409), TbCPR-2 (XM_822460), or TbCPR-3
(XM_823737) were amplified from T. brucei genomic DNA and cloned
into the trypanosomal expression vector pBSF-TbNTR-9e10 (27), such
that the insert DNA replaced the TbNTR gene. Constructs were digested
with AscI, and purified fragments were electroporated into T. brucei 2T1
BSF cells.
Drug assays. All assays were performed in a 96-well plate format. T.
brucei BSF parasites (200 cells per well) were treated with growthmedium
containing different concentrations of nitrofuran. Where appropriate,
protein expression was induced by adding tetracycline (1 g ml1). After
incubation at 37°C for 3 days, alamarBlue was added to each well and the
plates incubated for a further 8 h (40). The fluorescence of each culture
was determined using a Gemini fluorescent plate reader (Molecular De-
vices) at an excitation wavelength of 530 nm, emission wavelength of 585
nm, and an emission cutoff filter at 550 nm. The change in fluorescence
Antiparasitic Action of Nitrofuran Derivatives
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resulting from the reduction of alamarBlue is proportional to the number
of live cells. The concentration of compound that inhibited parasite
growth by 50% (IC50) was then established.
To assess mammalian cell cytotoxicity, Vero cells (2,000 cells per well)
were treated with growth medium containing different concentrations of
nitrofurans. After incubation at 37°C for 6 days, alamarBlue was added to
eachwell and the plates incubated for a further 8 h. The cell density of each
culture was determined as described above and the IC50 value was estab-
lished.
Biochemistry. Recombinant His-tagged TbNTR was purified from
Escherichia coli extracts as described previously (40). Enzyme activity was
determined by following the changes in absorbance at 400 nm corre-
sponding to the reduction of nitrofuran. A reaction mixture (1 ml) con-
taining 50mMTris-Cl (pH 7.0), 100MNADH, and nitrofuran (0 to 100
M) was incubated at room temperature for 5 min. The reaction was
initiated by the addition of 20 g trypanosomal NTR, and the initial
reaction rate was measured. In the case of HC17, no significant absor-
bance at 400 nm was observed. For reactions involving this substrate, the
change in absorbance at 340 nm was followed, corresponding to NADH
oxidation (extinction coefficient value of 6,220 mM1 cm1). For nifur-
timox, the change in absorbance at 435 nm was followed, corresponding
to the reduction of this compound (extinction coefficient value of 19,000
mM1cm1). For compounds HC1 to HC16, an extinction coefficient
value at 400 nm was calculated and used to determine enzyme activity
(Table 1). To standardize data values, enzyme activity was expressed in
nmol NADH oxidized min1 mg1, and it is assumed that four NADH
molecules are consumed during the reduction of one nitrofuranmolecule
(B.S.H. and S.R.W., unpublished data). Kinetic analysis (apparent Vmax,
kcat, and Km values standard deviations [SD]) was performed by non-
linear regression analysis using GraphPad Prism 5 (GraphPad Software).
As the kcat/Km value is derived from two parameters, each with their own
associated error, kcat/Km lower and upper error bar values were calculated
by using ([mean kcat  SD]/[mean Km  SD]) and ([mean kcat  SD]/
[mean Km SD]), respectively.
Analysis of metabolites. The substrate (nitrofurazone, HC1, HC2,
HC4, HC10, or HC11, all at 100 M) was completely reduced by the
activity of recombinant TbNTR (40 g ml1). The His-tagged enzyme
was removed by binding to nickel-nitrilotriacetic acid (Ni-NTA), the pro-
tein was pelleted, and the supernatant was analyzed using a Series 1100
liquid chromatograph (LC) with SL Ion Trap mass spectrometer (MS)
(Agilent). Fractionation was carried out on a 5-mm HyPurity Elite C18
column (15 mm by 2.1 mm) (Thermo Scientific) preequilibrated with
10% acetonitrile eluting with a 10 to 30% acetonitrile gradient at a flow
rate of 0.2 ml min1. Metabolites were detected using a diode array ( at
250, 300, 340, and 450 nm) andm/z was determined by positive electros-
pray ionization. Mass spectrometry was carried out with a drying gas
temperature of 325°C, drying gas flow of 10 liters min1, nebulizer gas
pressure of 25 lb/in2, and a capillary voltage of 3,500V in full scanmode in
the m/z range 50 to 400. Negative tandem mass spectrometry was per-
formed in automatic mode using SmartFrag for ion fragmentation.
RESULTS
Nitrofurans are substrates for the trypanosomal NTR.Most ni-
troheterocyclic compounds function as prodrugs and must un-
dergo activation before mediating cytotoxic effects. For the
trypanocidal agent nifurtimox, a type I NTR has been shown to
play a key role in this process (27). To evaluate whether other
nitrofuran-based compounds are activated via this mechanism, a
preliminary enzyme activity screen using purified recombinant
His-tagged T. brucei NTR was performed (Fig. 1A). The previ-
ously reported NTR assay that monitored the oxidation of NADH
TABLE 1 Structures of nitrofuran compounds
Compound n X R  (M1cm1)a CLogPb
Thiosemicarbazones
HC1 0 S NH2 12,300 0.75
HC2 0 S NHCH3 13,900 0.98
HC3 0 S NHCH2CH3 17,090 1.34
HC4 0 S NHCH2CHCH2 12,250 1.71
HC5 0 S NHPh 4,770 3.00
HC15 1 S NHCH3 4,570 1.27
HC16 1 S NHCH2CHCH2 7,940 0.33
Carbazates
HC6 0 O OCHCH2 6,390 1.32
HC7 0 O OCH3 9,840 0.82
HC8 0 O O(CH2)3CH3 8,840 2.14
HC9 0 O O(CH2)5CH3 2,010 3.03
HC10 0 O O(CH2)6CH3 7,040 3.48
HC11 0 O O(CH2)7CH3 2,120 3.92
HC12 0 O OPh 4,920 2.48
HC17 1 O OPh 2.77
Semicarbazones
Nitrofurazone 0 O NH2 12,000 0.14
HC13 0 O NH(CH2)3CH3 13,490 1.41
HC14 0 O NHCH2CH2OCH3 15,130 0.04
a The molar extinct coefficients () for HC1 to HC16 at 400 nm were determined. HC17 displayed no significant absorbance at this wavelength.
b CLogP values were determined using the ChemAxon CLogP calculator program.
Bot et al.
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could not be used here, as many nitrofurans displayed significant
absorbance at 340 nm (data not shown). Therefore, the direct
reduction of the nitroheterocycle itself was followed by monitor-
ing the change in absorbance at 400 nm (for HC1 to HC16 and
nitrofurazone) or 435 nm (for nifurtimox); the molar extinct co-
efficient for each compound was established (Table 1). For HC17,
no significant absorbance at 435, 400, or 340 nmwas observed, so
for reactions involving this substrate, the change in absorbance at
340 nm was followed, corresponding to NADH oxidation.
In total, 19 compounds, including nifurtimox and nitrofura-
zone, were screened against TbNTR. All structures contained a
common 5-nitrofuran core with different substituent groups at
the 2-position on the furan ring. Based on the nature of this side
chain, these compounds could be divided into thiosemicarba-
zones (HC1 to HC5, HC15, and HC16), semicarbazones (nitro-
furazone, HC13, and HC14), and carbazates (HC6 to HC12 and
HC17); nifurtimox is distinct in that the substituent contains a
thiomorpholine ring linked to nitrofuran by a hydrazone moiety.
For 3 derivatives (HC15 to HC17), an alkene linker group was
inserted between the thiosemicarbazone/carbazate chain and
furan ring. All compounds weremetabolized by the trypanosomal
enzyme, generating a higher activity, as judged by apparent Vmax
FIG 1 Analysis of TbNTR activity toward nitrofurans. (A) SDS-PAGE gel (10%) stained with Coomassie blue. Lane M, size standards; lane 1, recombinant
TbNTR purified as described previously (41). (B) In the presence of NADH (100 mM), the activity of purified His-tagged TbNTR was assessed by following the
reduction of the nitrofuran substrates at 400 nm (HC1 to HC16 and nitrofurazone) or 435 nm (nifurtimox [NFX]). For HC17, the oxidation of NADH at 340
nmwasmonitored due to the absorption properties of this compound. To standardize the data, activity was expressed in nmolNADHoxidizedmin1mg1 (see
Materials and Methods). (C) Catalytic efficiency (kcat/Km) of TbNTR toward different non-alkene-linkered nitrofurans. (D) The hydrophobicity of the nitro-
furans was determined (CLogP) using the ChemAxon CLogP calculator program and compared against the catalytic efficiency of TbNTR (kcat/Km) toward each
thiosemicarbazone (diamonds), semicarbazone (circles), and carbazate (triangles). (E) Comparison of CLogP with apparent Km values for thiosemicarbazone
(diamonds), semicarbazone (circles), and carbazate (triangles). For each compound, the enzyme activity using several nitrofurans (0 to 100M)was determined,
from which apparent Vmax, kcat, and Km values  standard deviations were generated by nonlinear regression analysis using GraphPad Prism 5 (GraphPad
Software). These kinetic values were then used to calculate kcat/Km values, with the associated error bars obtained by comparison of the kcat and Km standard
deviations (see Materials and Methods).
Antiparasitic Action of Nitrofuran Derivatives
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values, than that of nifurtimox (Fig. 1B). A comparison of the
catalytic efficiency of TbNTR toward each substrate revealed that
no single agent or class of nitrofuran (thiosemicarbazone, semi-
carbazone, or carbazate) was preferentially metabolized by the
parasite enzyme (Fig. 1C); kcat/Km values for the nitrofurans re-
ported here were between 6.5	 103 and 2.4	 105 M1s1, com-
pared to 3.6	 103 M1s1 for nifurtimox. For nitrofuran deriv-
atives containing an alkene linker, lower apparent Vmax values
were observed than for their nonlinkered counterparts (HC2 ver-
susHC15, HC4 versusHC16, andHC12 versusHC17) (Fig. 1B), a
difference manifested by their lower kcat/Km values (Fig. 1C); ni-
trofurans containing an alkene linker had a lower affinity for
TbNTR than their nonlinkered counterparts (Km for HC2 was
6.3  1.4 M versus 65.1  16.2 M for HC15; Km TbNTR for
HC4 was 6.1  1.4 M versus 57.9  15.6 M for HC16). An
associationwas observedwhen analyzing the relationship between
the catalytic efficiency values of TbNTR toward each non-alkene-
linkered compound and the calculated hydrophobicity (CLogP)
of each nitrofuran (Fig. 1D). This indicated that the more hydro-
phobic a substrate is, the higher its kcat/Km value. Given that the
apparentVmax values formost hydrophobic substrates are low, the
observed catalytic efficiencies are probably due to the higher af-
finities that such compounds have for the parasite enzyme, and
this is reflected in their low apparent Km values (Fig. 1E).
Trypanocidal activity of nitrofuran derivatives. The nitro-
furan derivatives used in this study were selected on the basis of
their anti-T. cruzi properties (33–36). To determinewhether these
agents also affected T. brucei, growth-inhibitory assays were per-
formed (Table 2). An initial screen revealed that only 1 of the 19
compounds (HC5) did not affect the growth of BSF trypanosomes
at concentrations up to 20M. For the remaining 18 compounds,
further studies revealed that 13 had IC50s of
1 M, with 6 yield-
ing values of
250 nM; these were the thiosemicarbazones HC1,
HC2, and HC4, the carbazates HC10 and HC11, and the semicar-
bazone nitrofurazone. In contrast to other nitroheterocyclic com-
pounds (41, 42), no relationship between the antiparasitic prop-
erties of nitrofurans and the enzymatic activities of TbNTR
toward these substrates was observed (Table 2; Fig. 1).
To demonstrate that the nitrofurans were metabolized by
TbNTR in the parasite itself, the susceptibilities of trypanosomes
with altered levels of the oxidoreductase were investigated (Fig. 2).
In most cases, cells expressing elevated levels of TbNTR (tet)
were between 4- and 15-fold-more sensitive to the nitrofurans
than controls (tet) (Table 3; Fig. 2A). For 1 compound,HC6, the
recombinant and wild-type lines displayed equivalent susceptibil-
ities. When the converse experiments were performed using
TbNTR heterozygous parasites, cells expressing lower levels of the
oxidoreductase were between 1.5- and 3-fold more resistant to
most nitrofurans than controls (Table 4; Fig. 2B). For two com-
pounds, HC6 and HC10, the recombinant and wild-type lines
displayed equivalent susceptibilities. In the case of HC6, the alter-
ation of TbNTR levels had no effect on the susceptibility of the
parasites to this derivative, suggesting that the trypanocidal activ-
ity of this nitrofuran does not involve the type I nitroreductase.
When the susceptibilities of TbNTR heterozygous lines and con-
trols to HC10 were investigated, similar IC50s were obtained,
whereas cells overexpressing this enzyme displayed hypersensitiv-
ity. This suggests that the metabolite(s) generated fromHC10 fol-
lowing TbNTR reductionmight be extremely toxic to the parasite
and that reducing the enzyme levels by half has little effect on the
trypanocidal activity of this drug; of all the 5-nitrofurans screened,
HC10 is the most potent agent against both BSF T. brucei and
mammalian cells.
Other parasite proteins have been postulated to interact with
nitrofuran derivatives. These include prostaglandin F2 synthase
and cytochrome P450 reductases, which are enzymes believed to
be activators of nifurtimox, and squalene epoxidase, which is hy-
pothesized to be directly inhibited by parent nitrofurans or me-
tabolites derived from nitroheterocycles (32, 33, 39). To examine
whether these enzymes affect or are affected by the 6 most potent
compounds identified through our screens, recombinant TbPGS,
TbCPR2, TbCPR3, or TbSQE was expressed in BSF parasites, as
described for TbNTR (Fig. 3). In all cases, the expression of these
other enzymes had no effect on parasite susceptibility (data shown
in Fig. 3 relates to HC2 and nitrofurazone, but all six compounds
behaved similarly); it must be noted that the expression of these
enzymes was determined through Western blot analysis and not
via functional activity. This indicates that in theT. brucei form that
is able to replicate in the mammalian host, these enzymes do not
play a significant role in the metabolism of the nitroheterocyclic
compounds.
Cytotoxicity of nitrofuran derivatives to mammalian cells.
The 6 compounds displaying the highest trypanocidal activities
(IC50s
 300 nM) against BSF T. brucei were assayed for cytotox-
icity against Vero cells (Table 2). The selectivity index (calculated
as a ratio of the IC50 against themammalian line to the IC50 against
the parasite) for each agent was then determined. In all cases, the 6
TABLE 2 Susceptibilities of bloodstream-form T. brucei and
mammalian cells to nitrofurans
Compound
IC50 SD (nM) Selectivity
indexcT. bruceia Verob
Nifurtimox 2,780 200 64,000 1,000 23
Thiosemicarbazones
HC1 180 10 24,000 1,000 133
HC2 200 10 22,000 1,000 110
HC3 500 50
HC4 240 303 20,000 1,000 83
HC5 20,000
HC15 670 20
HC16 790 40
Carbazates
HC6 540 70
HC7 1,430 90
HC8 2,520 330
HC9 1,650 60
HC10 120 20 14,000 1,000 116
HC11 170 11 45,000 2,000 264
HC12 380 40
HC17 430 60
Semicarbazones
Nitrofurazone 230 80 36,000 3,000 157
HC13 1,280 60
HC14 570 30
a Data shown are means SD from four experiments.
b Data shown are means SD from three experiments.
c The selectivity index (SI) was calculated as a ratio of the IC50 against Vero cells to the
IC50 against the parasite.
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compounds displayed selective toxicity toward the parasite in
vitro, having selectivity index values between 3- and 11-fold
greater than that of nifurtimox.
TbNTR reduces nitrofurans to open-chain nitriles. Reduc-
tion of nitroheterocyclic compounds by type I NTRs can result in
the formation of various metabolites (31, 43). To identify which
products are generated following TbNTR reduction, the 6 most
potent nitrofurans were enzymatically reduced and the resultant
material analyzed by liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) (Fig. 4). For all thiosemicarbazones (HC1,
HC2, and HC4), LC-MS analysis identified a single analyte whose
mass spectrum was compatible with the saturated open-chain ni-
trile form of the parent compound. In all cases, negative tandem
MS unequivocally confirmed the nature of this structure. For ex-
ample, HC2 reduction leads to formation of an m/z fragment for
[M-H] at 197 (Fig. 4A, peak a). This then fragments to yield four
ions with m/z values of 89, 97, 107, and 124 (Fig. 4B). These ions
are the result of the eliminative cleavage of weak N-N or N-C
bonds to give thioamide (m/z value of 89) and truncated open-
chain nitrile (m/z values of 107 and 124) forms, with the 124 ion
undergoing further fragmentation to release a nitrile moiety (m/z
value of 97) as NCH.
In the case of the semicarbazones (nitrofurazone) and carba-
zonates (HC10 andHC11), TbNTR-mediated reduction results in
two major products. The mass spectrum of one ion was compat-
ible with that of the unsaturated open-chain nitrile form of the
parent compound, while the secondmight have been generated by
either a saturated open-chain nitrile or an amine. For nitrofura-
zone, reduction led to the formation of two ions of [M-H] with
m/z values of 165 and 167 (Fig. 4C, peaks b and a, respectively),
with peak b corresponding to the unsaturated open-chain nitrile
and peak a representing the saturated open-chain nitrile or amine.
FIG 2 Susceptibility of the bloodstream form of T. bruceiwith varied levels of TbNTR to nitrofurans. Growth-inhibitory effects (IC50s inM) of HC2 and
nitrofurazone (NFZ) on T. brucei cells overexpressing (TbNTRox) (A) or with lowered levels (TbNTR
/) (B) of TbNTR are shown. Data are means from
4 experiments  the SD, and the differences in susceptibilities were statistically significant (P 
 0.01), as assessed by Student’s t test. The other 4 most
potent nitrofurans (HC1, HC4, HC10, and HC11) behaved similarly to HC2 and nitrofurazone. G418 and nifurtimox were used as drug controls.
TABLE 3 Susceptibilities of bloodstream-form T. brucei with elevated
levels of TbNTR to nitrofuransa
Compound
T. brucei IC50 SD (nM)
b
tet tet
Nifurtimoxc 2,890 30 315 15
Thiosemicarbazones
HC1 290 20 70 5
HC2 200 5 35 5
HC3 500 40 70 5
HC4 270 15 35 5
HC15 880 60 65 5
HC16 760 45 75 5
Carbazates
HC6 475 40 320 20
HC7 1,620 15 145 30
HC8 2,065 225 350 50
HC9 2,165 140 180 5
HC10 100 10 25 5
HC11 385 40 50 5
HC12 2,765 240 835 25
HC17 1,945 134 145 10
Semicarbazones
Nitrofurazone 165 5 40 5
HC13 1,165 140 75 5
HC14 625 15 160 5
G418c 640 10 540 20
a Growth-inhibitory effect as judged by the IC50s (in nM) of all nitrofuran compounds
on T. brucei control (tet) and TbNTR-overexpressing (tet) cells.
b Data shown are means from 4 experiments the standard deviations.
c G418 and nifurtimox were used as drug controls.
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To determine the nature of peak a, the saturated open-chain ni-
trile or amine ion was subjected to negative tandem MS. In all
cases, the resultant fragmentation profile was consistent with the
saturated open-chain nitrile. For nitrofurazone, negative tandem
MSon the 167 fragment (Fig. 4C, peak a) resulted in the formation
of two distinct ions with m/z values of 140 and 123. The 140 ion
was generated by the loss of the nitrile, asNCH, from the saturated
open-chain nitrile structure, while the 123 ion corresponds to the
loss of a carboxamide group at the opposite end of the molecule
(Fig. 4D).
DISCUSSION
The effectiveness of nitrofurans against T. brucei was demon-
strated40 years ago, although this promise did not immediately
translate to clinical treatments against HAT (7, 9). However, the
problems related to current therapies have stimulated a renewed
interest in using nitroaromatic compounds to target T. brucei (41,
42, 44), with NECT being added to theWHO Essential Medicines
List for the treatment ofWest African trypanosomiasis (11). Here,
we conducted a screening program against BSF T. brucei, making
use of a 5-nitrofuran series that was originally developed for use
against Chagas disease (33–36). Most compounds exhibited
higher activities toward BSF parasites than nifurtimox (Table 2),
although the 6 most potent agents (those with IC50s 
 300 nM)
were also toxic to mammalian cells. However, by virtue of their
effects on trypanosome growth, these 6 all had improved selectiv-
ities against the parasite compared to nifurtimox. Understanding
how these compounds mediate their antimicrobial activities may
help in developing trypanocidal derivatives with reduced host
toxicity.
Previous studies have shown that the type I nitroreductase-
mediated activation of nifurtimox is key to how this prodrug me-
TABLE 4 Susceptibilities of bloodstream-form T. brucei with reduced
levels of TbNTR to nitrofuransa
Compound
T. brucei IC50 (nM)
b
Wild-type TbNTR/
Nifurtimoxc 2,800 195 4,200 290
Thiosemicarbazones
HC1 180 5 320 10
HC2 200 15 560 35
HC3 500 45 760 5
HC4 240 35 1,295 30
HC15 665 20 1,080 125
HC16 790 40 1,350 95
Carbazates
HC6 535 70 620 25
HC7 1,430 90 2,100 135
HC8 2,520 330 4,595 550
HC9 1,650 65 2,930 250
HC10 120 15 140 15
HC11 170 5 310 55
HC12 380 40 700 75
HC17 430 60 765 1,250
Semicarbazones
Nitrofurazone 225 10 540 15
HC13 1,275 55 1,720 85
HC14 575 25 905 30
G418c 580 10 625 25
a Growth-inhibitory effect as judged by IC50s (in nM) of all nitrofuran compounds on
T. brucei wild-type parasites and TbNTR heterozygous line (designated TbNTR/).
b Data shown are the means from 4 experiments the standard deviations.
c G418 and nifurtimox were used as drug controls.
FIG 3 Susceptibility of the bloodstream form ofT. brucei ectopically expressing other enzymes proposed to interact with nitrofurans. (A) Blot containing lysates
(10 g) from the bloodstream forms of uninduced (1) and tetracycline-induced (2) cultures probed with a 9E10 antibody (Merck Millipore). Extracts were
generated from cells induced to express c-Myc-tagged TbPGS, TbCPR2, TbCPR3, or TbSQE. Protein loading was judged by Coomassie blue staining (not
shown). (B andC)Growth-inhibitory effect (IC50s inM)ofHC2 (B) and nitrofurazone (C) onT. brucei cells induced to express recombinant TbPGS, TbCPR2,
TbCPR3, or TbSQE. The other 4 most potent nitrofurans (HC1, HC4, HC10, and HC11) behaved similarly to HC2 and nitrofurazone. Data shown are means
from 4 experiments the SD.
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diates its antiparasitic selectivity (25, 27). Using biochemical and
phenotypic screens, we demonstrated that this activation mecha-
nism extended to most of the 5-nitrofuran series examined here.
In vitro studies revealed that all compounds were metabolized by
purified TbNTR (Fig. 1B), with the enzyme having a high affinity
for hydrophobic substrates (Fig. 1E), while parasite lines express-
ing elevated or reduced levels of TbNTR had altered susceptibili-
ties tomost of these agents (Tables 3 and 4; Fig. 2). This activation
step appears to be TbNTR-specific, as phenotypic screening using
parasite lines expressing elevated levels of cytochrome P450 re-
ductase or prostaglandin F2 synthase, which are enzymes postu-
lated to activate 5-nitrofurans (32, 39), had no effect on parasite
susceptibility (Fig. 3). This is not to say that the 5-nitrofuran de-
rivatives do not act as substrates for cytochromeP450 reductase or
prostaglandin F2 synthase, merely that any interaction with
these enzymes is not the primary route of parasite growth inhibi-
tion. Treatment of T. cruzi with certain nitrofurans leads to an
intracellular accumulation of squalene, a phenomenon attributed
to the inhibition of squalene epoxidase (33). Overexpression of
this enzyme in BSF parasites did not affect the susceptibility of the
trypanosomes to the most potent nitrofurans and indicates that
these agents do not mediate their anti-T. brucei activities through
squalene epoxidase inhibition.Why the nitrofurans appear to dis-
play distinct mechanisms of action toward these two trypano-
somes species might reflect differences in the relative importance
of the sterol biosynthesis pathway to these organisms; this path-
way has long been regarded as a chemotherapeutic target against
Chagas disease, while BSF T. brucei can readily scavenge these
organic molecules from their environment (45).
To characterize any stable products arising from TbNTR-me-
diated reduction of selected 5-nitrofurans, an analysis of the me-
tabolites was performed using liquid chromatography coupled to
tandem mass spectrometry. Using the semicarbazone nitrofura-
zone, two major end products were isolated and identified as sat-
urated and unsaturated open-chain nitrile derivatives (Fig. 4).
During nitrofuran reduction with bacterial type I nitroreductases,
the saturated form is frequently detected, whereas the unsaturated
structure, although postulated as an intermediate (13), is not.
Toxicity studies have shown that the saturated form does not af-
fect cell growth, resulting in the hypothesis that the intermediates
generated during its formation are responsible for the antimicro-
bial properties of this prodrug. In contrast, analysis of the metab-
olites generated following nifurtimox reduction by the T. cruzi or
T. brucei type I nitroreductases identified the unsaturated open-
chain nitrile as the major end product, which then undergoes
further reduction to the saturated form, albeit at a very low rate
(25). Analysis of the toxicity of the unsaturated form demon-
strated that this affected T. brucei and mammalian cells at equiv-
alent levels, unlike the parental prodrug, which shows selectivity
toward the parasite. The data reported here clearly show that fol-
lowing the initial nitrofurazone reduction, conversion of the un-
saturated to saturated form occurs more readily than for nifurti-
mox. Based on the above reports, it is tempting to speculate that
the trypanocidal activity displayed by nitrofurazone stems from
the unsaturated open-chain nitrile, at least in part. However, the
effects of other, unstable intermediaries cannot be ruled out at this
stage. When analyzing two structurally related carbazate deriva-
tives (HC10 and HC11), the corresponding unsaturated and sat-
FIG 4 Characterizing the TbNTR-mediated nitrofuran reduction products. (A) Negative enhanced MS (EMS)-MS analysis of the TbNTR-mediated HC2
reduction product identifies a single analyte (peak a) whose mass spectrum contained a molecular ion for [M-H] with m/z values of 197. (B) Negative
electrospray ionization (ESI) MS-MS analysis of peak a (identified in panel A) generates [M-H] ions withm/z values of 90, 97, 107, and 124. Analysis of these
fragments indicates that the [M-H] ion having an m/z value of 198 corresponds to a saturated open-chain nitrile (molecular weight of 198). (C) Negative
EMS-MS analysis of the TbNTR-mediated nitrofurazone reduction products identifies two ions (peaks a and b) withm/z values of 167 (peak a) and 165 (peak
b). (D) Negative ESIMS-MS analysis of them/z 167metabolite (identified in panel C) generates [M-H] ions withm/z values of 124 and 140. Fragment analysis
indicates that the [M-H] ion having an m/z value of 167 corresponds to a saturated open-chain nitrile structure, while the m/z 165 ion corresponds to its
unsaturated derivative.
Antiparasitic Action of Nitrofuran Derivatives
April 2013 Volume 57 Number 4 aac.asm.org 1645
 o
n
 M
arch 14, 2013 by Queen M
ary, University of London
http://aac.asm
.org/
D
ow
nloaded from
 
urated end products were also observed (data not shown), indi-
cating that this reaction is common to many semicarbazone- and
carbazate-based nitrofuran derivatives and is therefore unlikely to
be an experimental artifact.
When these studieswere extended to thiosemicarbazone deriv-
atives (HC1, HC2, and HC4), only the saturated open-chain ni-
trile endmetabolite was observed (Fig. 4). Presumably, the unsat-
urated open-chain nitrile metabolites resulting from the type I
nitroreductase-mediated reactions are too unstable to isolate with
this analytical technique. The obvious difference between these
compounds and those described earlier is the presence of the
much bulkier sulfur-containing thiosemicarbazone group in
place of the oxygen-based semicarbazone group, which might in-
fluence the stability of any intermediates.
As noted, nitroheterocyclic drugs are experiencing a renais-
sance as treatments for HAT, with nifurtimox being deployed
alongside eflornithine against theWest African form and the 5-ni-
troimidazole fexinidazole entering phase I clinical trials (www
.dndi.org). Fexinidazole activity against T. brucei was first discov-
ered almost 30 years ago, yet its full potential has only recently
been appreciated (44). While it has yet to be explicitly demon-
strated that fexinidazole is activated by the trypanosomal type I
nitroreductase, it is noteworthy that aT. brucei cell line resistant to
nifurtimox shows cross-resistance to fexinidazole (46). Likemany
nitroheterocyclic drugs, fexinidazole fails the “classical” Ames test
of mutagenicity, yet it is not mutagenic to type I nitroreductase-
deficient bacteria or to mammalian cells (44). Whether the type I
nitroreductase-mediated activation of nitroheterocyclic drugs,
such as nifurtimox and fexinidazole, to their toxic metabolites is
the sole cause of all short- and long-term cytotoxic effects ob-
served remains unclear and seems unlikely, given the observation
of nitroheterocyclic drug metabolites in animal tissues (47, 48).
Therefore, perhaps themore subtle question to be addressed is, do
nitroheterocyclic drugs have the potential to be designed with
enough specificity towards the trypanosomatid type I nitroreduc-
tase, so as to present only a reasonable risk for acceptable associ-
ated side effects to human patients over both the short and
longterm? Appreciating the shared mechanisms of nitroaromatic
drug activation and predicting the downstreammetabolites across
many classes of compounds by the trypanosomal nitroreductase
are fundamental aspects of overcoming this challenge.
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